๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› AML
Clinical trial register · China

AML Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 12 Beijing 5 Chengdu 2 Shanghai 2 Fuzhou 2
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin12 Beijing5 Chengdu2 Shanghai2 Fuzhou2
All 12 locations
Target enrolment
to

AML trials in China

26 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
NCT07490288AML
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
27
Tianjin
2026-05-08
Recruiting
Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
NCT07617285AML, Refractory/Relapse Acute Myeloid Leukemia
Peking University People's Hospital
Phase 1
27
Beijing
2026-05-07
Not yet open
Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT07342244AML, AML (Acute Myeloid Leukemia)
Donghua Zhang
Not applicable
18
Wuhan
2026-01-30
Recruiting
Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.
NCT06946602AML, Elderly
Peking University People's Hospital
Not applicable
307
Beijing
2026-01-01
Recruiting
Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity
NCT07587944AML, Adult
Fujian Medical University Union Hospital
Observational
405
Fuzhou
2025-12-01
Recruiting
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
NCT06611839AML, IDH1 Mutation, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
23
Tianjin
2025-10-17
Recruiting
Leptin: A Marker for AML Chemo-Sensitivity
NCT07163728AML, Adult
Fujian Medical University Union Hospital
Observational
86
Fuzhou
2025-08-01
Recruiting
The Efficacy and Safety Assessment of Allogeneic ฮณฮด T Cells in Patients With MRD-positive AML After Allo-HSCT
NCT07126782AML (Acute Myelogenous Leukemia), AML
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
10
Beijing
2025-07-20
Recruiting
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
NCT06972641AML, MDS
Ruijin Hospital
Phase 2/3
126
Shanghai
2025-06-10
Recruiting
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
NCT07347171Leukemia, AML, MDS, AML (Acute Myelogenous Leukemia)
Cullgen (Shanghai),Inc
Phase 1
45
Nanchang, Tianjin, Wuhan
2025-04-17
Active, closed
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
NCT06744556AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
41
Tianjin
2025-01-21
Recruiting
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
NCT06744504AML, RUNX1-RUNX1T1 Fusion Protein Expression
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
284
Tianjin
2025-01-10
Not yet open
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia
NCT06643195AML
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
358
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2025-01-01
Recruiting
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
NCT06741722AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2
20
Beijing
2024-10-31
Recruiting
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
NCT06561880FLT3 Gene Mutation, AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
66
Tianjin
2024-10-08
Recruiting
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
NCT06529250AML
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
148
Tianjin
2024-08-13
Recruiting
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
NCT06386302AML, Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
184
Tianjin
2024-08-05
Recruiting
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
NCT06420063AML, Acute Myeloid Leukemia, AML, Adult Recurrent, AML, Adult
Essen Biotech
Phase 1/2
85
Beijing
2024-07-10
Recruiting
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS
NCT06731699AML, NHL
Chengdu FenDi Pharmaceutical Co., Ltd.
Phase 1
72
Chengdu
2024-03-11
Recruiting
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
NCT06265545AML, Refractory, Relapsed
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
458
Tianjin
2024-02-22
By invitation
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
NCT06499025AML, t(8;21), Neoantigen
BGI, China
Phase EARLY_PHASE1
16
Shenzhen
2024-02-01
Not yet open
A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure
NCT05875649AML
Nanfang Hospital, Southern Medical University
Observational
137
Guanzhou
2023-07-02
Recruiting
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
NCT05736978AML, MRD
Shanghai Tong Ren Hospital
Phase 2
58
Shanghai
2023-03-31
Active, closed
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML
NCT03021330AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
1,100
Tianjin
2017-02-08
Active, closed
Efficacy and Safety of Chidamide in CBF Leukemia
NCT03031262AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
250
Tianjin
2017-02-08
By invitation
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
NCT03031249AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
80
Tianjin
2017-02-08
Rows per page Showing 1–26 of 26
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/aml

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 26 of those studies listing the condition AML.

How many AML trials are recruiting in China?

18 of the 26 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 3 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (AML), 26 studies
PhaseStudiesRecruitingShare
Not applicable7526.9%
Phase 1/25319.2%
Observational3211.5%
Phase 13311.5%
Phase 23211.5%
Phase 3217.7%
Phase EARLY_PHASE1217.7%
Phase 2/3113.8%

Most active sponsors

Lead sponsors with the most studies (AML)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China138
Fujian Medical University Union Hospital22
Peking University People's Hospital22
Beijing 302 Hospital11
BGI, China10
Chengdu FenDi Pharmaceutical Co., Ltd.11
Cullgen (Shanghai),Inc11
Donghua Zhang10
Essen Biotech11
Nanfang Hospital, Southern Medical University10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.